Neoadjuvant Immunotherapy in Resectable Non-Small Cell Lung Cancer. A Narrative Review

Lung cancer is one of the most common malignant tumors and it is the leading cause of cancer-related mortality worldwide. For early-stage Non-Small Cell Lung Cancer (NSCLC), surgical resection is the treatment of choice, but the 5-year survival is still unsatisfying, ranging from 60% to 36% dependin...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatteschi, Lavinia, Iannopollo, Mauro, Gonfiotti, Alessandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539920/
https://www.ncbi.nlm.nih.gov/pubmed/34685407
http://dx.doi.org/10.3390/life11101036

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539920/
https://www.ncbi.nlm.nih.gov/pubmed/34685407
http://dx.doi.org/10.3390/life11101036

Ejemplares similares